Renaissance Capital logo

NGM Biopharmaceuticals Priced, Nasdaq: NGM

Phase 2 biotech developing therapies for NASH and type 2 diabetes.

Industry: Health Care

First Day Return: -8.1%

Industry: Health Care

We are a clinical-stage biopharmaceutical company developing novel therapeutics based on our scientific understanding of key biological pathways underlying cardio-metabolic, liver, oncologic and ophthalmic diseases. These diseases are among the largest unmet medical needs globally and represent leading causes of morbidity and mortality and a significant burden for healthcare systems. Since the commencement of our operations in 2008, we have generated a robust portfolio of seven product candidates, five of which are in clinical testing. Our most advanced product candidate, NGM282, is wholly-owned and will enter Phase 2b development for the treatment of non-alcoholic steatohepatitis, or NASH, in mid-2019. In an ongoing Phase 2 clinical trial, NGM282 has demonstrated the ability to rapidly improve NASH and reverse liver fibrosis at 12 weeks. Our other programs are in Phase 1 clinical or preclinical testing and subject to our Merck collaboration.
more less
IPO Data
IPO File Date 09/28/2018
Offer Price $16.00
Price Range $14.00 - $16.00
Offer Shares (mm) 6.7
Deal Size ($mm) $107
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 04/03/2019
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $107
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters South San Francisco, CA, United States
Founded 2007
Employees at IPO 153
Website www.ngmbio.com

NGM Biopharmaceuticals (NGM) Performance